Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the world's largest association of facial plastic and reconstructive surgeons, has released its highly anticipated 2024 ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Some people who use semaglutide (Ozempic, others) have noted sagging skin in the buttocks, calling it “Ozempic butt.” While lifestyle modifications may help prevent this weight loss side ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

A nationwide shortage of Ozempic is impacting the ability of people with diabetes to access the drug, especially in regional and remote Australia. The Therapeutic Goods Administration says there ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the American Academy of Facial Plastic and Reconstructive Surgery. The group's ...